FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD – HCPLive
The FDA issued a Complete Response Letter for sotagliflozin in type 1 diabetes with chronic kidney disease, citing risk-benefit concerns.
The FDA issued a Complete Response Letter for sotagliflozin in type 1 diabetes with chronic kidney disease, citing risk-benefit concerns.